Table 6 (A) Dose reduction in prescriptions with BSA > 2 m2, (B) Dose reduction induced by BSA capping according to the intent of treatment.
From: Body surface area capping may not improve cytotoxic drugs tolerance
(A) Dose reduction | Capped prescription (N = 3705) | Uncapped prescription (N = 2030) | ||
|---|---|---|---|---|
N | % | N | % | |
Yes | 631 | 17.7 | 383 | 18.86 |
No | 3074 | 82.3 | 1647 | 81.14 |
(B) Intent of treatment | Dose reduction | N | % | |
|---|---|---|---|---|
Curative | 0–3% | 654 | 43.25 | |
3–20‚% | 849 | 56.15 | ||
> 20 | 9 | 0.60 | ||
Sub-total | 1512 | 100 | ||
Palliative | 0–3% | 843 | 38.46 | |
3–20% | 1341 | 61.18 | ||
> 20 | 8 | 0.36 | ||
Sub-total | 2192 | 100 | ||
